Compare Crispr Therapeutics AG (CRSP) vs Ishares Msci Brazil ETF (EWZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Ishares Msci Brazil ETF — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Ishares Msci Brazil ETF trades at $35.75. The key difference: Ishares Msci Brazil ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | EWZ | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $76.78 | $41.75 |
52-Week Low | $44.34 | $26.52 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
EWZ, the iShares MSCI Brazil ETF, trades at $35.39, down 1.5% for the day, with a bullish technical signal driven by moving averages. The ETF has gained approximately 11% year-to-date, supported by Brazil's monetary easing cycle and commodity strength. Recent news highlights its exposure to Latin America's equity rally and potential from Brazil's $10 billion Eco Invest auction aimed at sustainable technologies.
The outlook for EWZ is positive, with upside from Brazil's rate cuts and commodity markets, but risks include dependence on volatile commodity prices and potential derailment of the easing cycle. The ETF offers a discounted entry to Brazilian equities, yet payout consistency is a concern due to its concentrated holdings in firms like Petrobras and Vale.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →
